* For illustration purpose only
Champix (Varenicline)
In Stock
Commercial Name: Champix
Principal Ingredient: Varenicline
Utilization: Quitting Tobacco
Available Dosage: 0.5mg
* Prices in the list do not apply to Switzerland, Sweden and Denmark. Customers are advised to place an order, and our team will contact back with updated prices.
Last purchase: 19 minutes ago
There are 19 users looking at this product right now
Champix Overview
Champix is intended for the treatment of nicotine addiction. Champix has high binding affinity and selectivity. Nicotine is intensely bound to a similar receptor site to which Champix has a higher binding affinity. Due to the use of Champix, the craving for smoking is reduced and the manifestation of withdrawal symptoms is facilitated.
At the same time, the feeling of pleasure from smoking decreases (antagonism in the presence of nicotine). According to clinical studies, Champix has a statistically significant advantage over bupropion. Additionally, Champix significantly reduces the effects of reinforcement that occur during smoking and can reinforce the habit of smoking in patients who smoke during therapy.
Patients who do not want or cannot set a goal to quit smoking for 1–2 weeks may be asked to start therapy with the option to choose their own smoking cessation date within a range of 5 weeks. Patients who previously tried to quit smoking using Champix and who received Champix treatment repeatedly, compared with placebo, have the best level of proven persistent abstinence.
The biotransformation of Champix is minimal: only 92% of the dose is excreted unchanged by the kidneys, less than 10% as metabolites.
Kidney removal is mainly carried out by glomerular filtration in combination with active tubular secretion. The pharmacokinetic processes of Champix do not significantly depend on status, age, sex, race, or concomitant therapy of a person.
Medically reviewed by Dr. Josette Davignon
Last updated: 25.11.2024
